Haleon plc: Board
Change
25
February 2025: Haleon plc (the
"Company" or "Haleon") (LSE/NYSE: HLN) today announces the
following change to the Board.
Following the reduction of Pfizer
Inc.'s shareholding in Haleon plc below 10%, and in line with the
Pfizer Relationship Agreement with Haleon plc, Bryan Supran,
Non-Executive Director and representative of Pfizer
Inc., stepped down from the Board on 25 February 2025.
Sir
Dave Lewis, Haleon's Chair commented: "On
behalf of the Board, I would like to thank Bryan for his
contributions to the Board's discussions and for being part of the
Haleon journey from the initial joint-venture in 2019 through
demerger to today. We wish him all the very best for the
future."
The Company confirms that there is no further
information to be disclosed under the requirements of UKLR
6.4.6R.
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global
leader in consumer health, with a purpose to deliver better
everyday health with humanity. Haleon's product portfolio spans
five major categories - Oral Health, Pain Relief, Respiratory
Health, Digestive Health and Other, and Vitamins, Minerals and
Supplements (VMS). Its long-standing brands - such as Advil,
Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident,
parodontax and Centrum - are built on trusted science, innovation
and deep human understanding.
For more information, please
visit www.haleon.com.
